Adicet Bio, Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2020-09-15

Reporting Person: Schindel Yair Chaim (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-15	Common Stock	A	1104460	—	Acquired	1104460	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-17	Non-Qualified Stock Option (right to buy)	$16.11	A	30000	Acquired	2030-09-16	Common Stock (30000)	Direct

Footnotes

F1: The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2: Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc."

F3: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date.